Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib-Reference-Cited by-同舟云学术

Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib

Published:2018-11-02 Issue:4 Volume:8 Page:255-270
ISSN:2235-1795
Container-title:Liver Cancer
language:en
Short-container-title:Liver Cancer

Author:

Labeur Tim A.,van Vugt Jeroen L.A.,Ten Cate David W.G.,Takkenberg R. Bart,IJzermans Jan N.M.,Groot Koerkamp Bas,de Man Robert A.,van Delden Otto M.,Eskens Ferry A.L.M.,Klümpen Heinz-Josef

Publisher

S. Karger AG

Subject

Oncology,Hepatology

Reference29 articles.

1. European Association for the Study of the Liver European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908–43.

2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25–34.

3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul;359(4):378–90.

4. Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017 Nov;67(5):999–1008.

5. Hornecker M, Blanchet B, Billemont B, Sassi H, Ropert S, Taieb F, et al. Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs. 2012 Oct;30(5):1991–2000.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic immune regulation and sex disparities;Nature Reviews Gastroenterology & Hepatology;2024-09-05

2. Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial;United European Gastroenterology Journal;2024-07-15

3. The Clinical Significance of Myosteatosis in Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib;Cancers;2024-01-20

4. Development and validation of a clinical factors and body fat distribution-based nomogram to predict refractoriness of transarterial chemoembolization in hepatocellular carcinoma;Quantitative Imaging in Medicine and Surgery;2024-01

5. Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis;Frontiers in Nutrition;2023-10-19